TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Status:
Completed
Trial end date:
2011-09-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA
200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days
for the treatment of ABSSSI in adults.
Approximately 75 to 100 sites globally will participate in this study. Patients with an
ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be
randomized 1:1 to study treatment